FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569281657> ?p ?o ?g. }

• W2569281657 abstract "Abstract Once thought to be a natural killer cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, also termed CD4+CD56+ hematodermic neoplasm, is a rare clinical entity which derives from plasmacytoid dendritic cells. Cutaneous predominant (with better prognosis) and non-cutaneous subtypes (often accompanied by mediastinal involvement and a poorer prognosis) have been described. Many patients are treated with CHOP-like regimens, but the prognosis remains poor. Patients presenting with only skin lesions (median survival 21 months) had a better prognosis than patients presenting with both cutaneous and extra-cutaneous disease. We describe an 86 yo female with a distant history of breast cancer. She noted rapid development of mildly itchy round pink cutaneous nodlues on the arms, buttock, and legs. She was treated with topical steroids without improvement. The CBC, calcium, and LDH were normal. ECOG 0. There was no adenopathy or organomegaly. Skin biopsy demonstrated a dense lymphoid infiltrate involving the upper and mid dermis, as well as adnexal structures, without epidermotropism. The infiltrate was composed predominantly of large to intermediate sized lymphoid cells having moderate amounts of cytoplasm and oval to cleaved nuclei having open chromatin and one or more small nucleoli. Mitotic figures were present. The neoplastic cells expressed CD4, CD56. Ki-67 was expressed by many of the cells. The cells were negative for CD1a, CD3, CD5, CD7, CD8, PAX-5, CD20, CD79a, CD10, CD23, CD30, CD163, bcl-2, bcl-6, myeloperoxidase, kappa/lambda light chains, p63, Tdt, tryptase, chromogranin, MART-1, mammoglobin, CAM 5.2, and AE1/3. The morphology and immunophenotype was consistent with a CD4+/CD56+ hematodermic neoplasm. The patient preferred no additional staging studies or therapy. Based on the available data, cutaneous-only disease was suggested. The disease was observed without intervention for a few weeks, but progressed on her skin. She then requested a gentle therapy that might provide palliative improvement and prevent progression. Gemcitabine (2′,2′-difluorodeoxycytidine) is a well tolerated pyrimidine antimetabolite that impairs DNA synthesis and promotes induction of apoptosis. In patients with relapsed or refractory aggressive non-Hodgkin lymphoma, gemcitabine led to a 20% response rate with median survival of 6 months. Therapy with Gemcitabine was administered at 1000 mg/M2 on days 1, 8, 15 every 28 days. There was rapid and marked improvement of the skin nodules. Treatment was very well tolerated with minimal bilateral leg edema. A 4 week chemotherapy holiday was associated with regrowth. Photographs document the disease progression before therapy and response of disease with ongoing therapy. Gemcitabine may provide palliative benefit in some patients with blastic plasmacytoid dendritic cell neoplasm. Table Pre Therapy May 15 2014 Day 1 Chemotherapy May 23 2014 Day 22 Chemotherapy June 6 2014 Figure 1 Figure 1. Figure 2 Figure 2. Figure 3 Figure 3. Disclosures Off Label Use: Gemcitabine in blastic plasmacytoid dendritic cell neoplasm (CD4+CD56+ hematodermic neoplasm)." @default.
• W2569281657 created "2017-01-13" @default.
• W2569281657 creator A5002837242 @default.
• W2569281657 creator A5073727333 @default.
• W2569281657 date "2014-12-06" @default.
• W2569281657 modified "2023-10-02" @default.
• W2569281657 title "Gemcitabine in Blastic Plasmacytoid Dendritic Cell Neoplasm (CD4+CD56+ hematodermic neoplasm)" @default.
• W2569281657 doi "https://doi.org/10.1182/blood.v124.21.5457.5457" @default.
• W2569281657 hasPublicationYear "2014" @default.
• W2569281657 type Work @default.
• W2569281657 sameAs 2569281657 @default.
• W2569281657 citedByCount "3" @default.
• W2569281657 countsByYear W25692816572017 @default.
• W2569281657 countsByYear W25692816572018 @default.
• W2569281657 countsByYear W25692816572019 @default.
• W2569281657 crossrefType "journal-article" @default.
• W2569281657 hasAuthorship W2569281657A5002837242 @default.
• W2569281657 hasAuthorship W2569281657A5073727333 @default.
• W2569281657 hasConcept C113067387 @default.
• W2569281657 hasConcept C142724271 @default.
• W2569281657 hasConcept C147483822 @default.
• W2569281657 hasConcept C18031839 @default.
• W2569281657 hasConcept C196166836 @default.
• W2569281657 hasConcept C203014093 @default.
• W2569281657 hasConcept C204232928 @default.
• W2569281657 hasConcept C2776051438 @default.
• W2569281657 hasConcept C2778170410 @default.
• W2569281657 hasConcept C2779338263 @default.
• W2569281657 hasConcept C70905583 @default.
• W2569281657 hasConcept C71924100 @default.
• W2569281657 hasConcept C77231918 @default.
• W2569281657 hasConceptScore W2569281657C113067387 @default.
• W2569281657 hasConceptScore W2569281657C142724271 @default.
• W2569281657 hasConceptScore W2569281657C147483822 @default.
• W2569281657 hasConceptScore W2569281657C18031839 @default.
• W2569281657 hasConceptScore W2569281657C196166836 @default.
• W2569281657 hasConceptScore W2569281657C203014093 @default.
• W2569281657 hasConceptScore W2569281657C204232928 @default.
• W2569281657 hasConceptScore W2569281657C2776051438 @default.
• W2569281657 hasConceptScore W2569281657C2778170410 @default.
• W2569281657 hasConceptScore W2569281657C2779338263 @default.
• W2569281657 hasConceptScore W2569281657C70905583 @default.
• W2569281657 hasConceptScore W2569281657C71924100 @default.
• W2569281657 hasConceptScore W2569281657C77231918 @default.
• W2569281657 hasLocation W25692816571 @default.
• W2569281657 hasOpenAccess W2569281657 @default.
• W2569281657 hasPrimaryLocation W25692816571 @default.
• W2569281657 hasRelatedWork W1461775038 @default.
• W2569281657 hasRelatedWork W1488617127 @default.
• W2569281657 hasRelatedWork W1998287873 @default.
• W2569281657 hasRelatedWork W2002568523 @default.
• W2569281657 hasRelatedWork W2085896942 @default.
• W2569281657 hasRelatedWork W2096243554 @default.
• W2569281657 hasRelatedWork W2100664923 @default.
• W2569281657 hasRelatedWork W2115360769 @default.
• W2569281657 hasRelatedWork W2129384795 @default.
• W2569281657 hasRelatedWork W2411402264 @default.
• W2569281657 hasRelatedWork W2469896181 @default.
• W2569281657 hasRelatedWork W2565914359 @default.
• W2569281657 hasRelatedWork W2780157322 @default.
• W2569281657 hasRelatedWork W2795861786 @default.
• W2569281657 hasRelatedWork W2979693361 @default.
• W2569281657 hasRelatedWork W2991893139 @default.
• W2569281657 hasRelatedWork W3097365264 @default.
• W2569281657 hasRelatedWork W3160774062 @default.
• W2569281657 hasRelatedWork W87697501 @default.
• W2569281657 hasRelatedWork W2567407566 @default.
• W2569281657 isParatext "false" @default.
• W2569281657 isRetracted "false" @default.
• W2569281657 magId "2569281657" @default.
• W2569281657 workType "article" @default.